This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ince, D. Articles by Hooper, D. C. Search for Related Content PubMed PubMed Citation Articles by Ince, D. Articles by Hooper, D. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1410-1415, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1410-1415.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activity of and Resistance to Moxifloxacin in Staphylococcus aureus

Division of Infectious Diseases and Medical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2696

Received 17 September 2002/ Returned for modification 25 November 2002/ Accepted 20 December 2002

Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. Despite similar activity against purified S. aureus topoisomerase IV and DNA gyrase, it selects for topoisomerase IV mutants, making topoisomerase IV the preferred target in vivo.

This article has been cited by other articles:

• Black, M. T., Stachyra, T., Platel, D., Girard, A.-M., Claudon, M., Bruneau, J.-M., Miossec, C. (2008). Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases. Antimicrob. Agents Chemother. 52: 3339-3349 [Abstract] [Full Text]  
• Grossi, O., Caillon, J., Arvieux, C., Jacqueline, C., Bugnon, D., Potel, G., Hamel, A. (2007). In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model. Antimicrob. Agents Chemother. 51: 3401-3403 [Abstract] [Full Text]  
• Cheng, J., Thanassi, J. A., Thoma, C. L., Bradbury, B. J., Deshpande, M., Pucci, M. J. (2007). Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2445-2453 [Abstract] [Full Text]  
• Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., Grillot, A.-L., Stamos, D., Olson, E. R., Charifson, P. S., Mani, N. (2007). Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds. Antimicrob. Agents Chemother. 51: 657-666 [Abstract] [Full Text]  
• Bhagwat, S. S., Mundkur, L. A., Gupte, S. V., Patel, M. V., Khorakiwala, H. F. (2006). The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase . Antimicrob. Agents Chemother. 50: 3568-3579 [Abstract] [Full Text]  
• Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C. (2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother. 49: 5051-5057 [Abstract] [Full Text]  
• Korzheva, N., Davies, T. A., Goldschmidt, R. (2005). Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 49: 2479-2486 [Abstract] [Full Text]  
• Strahilevitz, J., Hooper, D. C. (2005). Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrob. Agents Chemother. 49: 1949-1956 [Abstract] [Full Text]  
• Campion, J. J., McNamara, P. J., Evans, M. E. (2005). Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 209-219 [Abstract] [Full Text]  
• Grohs, P., Podglajen, I., Gutmann, L. (2004). Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations. Antimicrob. Agents Chemother. 48: 3024-3027 [Abstract] [Full Text]  
• Wang, M., Sahm, D. F., Jacoby, G. A., Zhang, Y., Hooper, D. C. (2004). Activities of Newer Quinolones against Escherichia coli and Klebsiella pneumoniae Containing the Plasmid-Mediated Quinolone Resistance Determinant qnr. Antimicrob. Agents Chemother. 48: 1400-1401 [Abstract] [Full Text]  
• Ince, D., Hooper, D. C. (2003). Quinolone Resistance Due to Reduced Target Enzyme Expression. J. Bacteriol. 185: 6883-6892 [Abstract] [Full Text]